Pilgrim Hospital is a hospital in the east of Lincolnshire on the A16, north of the town of Boston near the mini-roundabout with the A52. It is situated virtually on the Greenwich Meridian and adjacent to Boston High School.

There are 391 beds in United Lincolnshire Hospitals NHS Trust.

During the past decade, United Lincolnshire Hospitals NHS Trust conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "United Lincolnshire Hospitals NHS Trust" #1 sponsor was "Celgene" with 4 trials, followed by "Incyte Corporation" with 3 trials sponsored, "University of Nottingham" with 3 trials sponsored, "Nottingham University Hospitals NHS Trust" with 1 trials sponsored and "United Lincolnshire Hospitals NHS Trust" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "United Lincolnshire Hospitals NHS Trust" #1 collaborator was "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "National Institute for Health Research, United Kingdom" with 1 trials as a collaborator, "University of Cambridge" with 1 trials as a collaborator and "University of Lincoln" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "United Lincolnshire Hospitals NHS Trust" are "Myelofibrosis" (4 trials), "Primary Myelofibrosis" (4 trials), "Anemia" (2 trials), "Post Essential Thrombocythemia Myelofibrosis" (2 trials) and "Post Polycythemia Vera Myelofibrosis" (2 trials). Many other conditions were trialed in "United Lincolnshire Hospitals NHS Trust" in a lesser frequency.

Most popular intervention types in "United Lincolnshire Hospitals NHS Trust" are "Drug" (8 trials), "Other" (3 trials), "Behavioral" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "ruxolitinib" (3 trials), "Oral Azacitidine" (2 trials), "Placebo" (2 trials), "parsaclisib" (2 trials) and "placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "United Lincolnshire Hospitals NHS Trust" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "United Lincolnshire Hospitals NHS Trust". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in United Lincolnshire Hospitals NHS Trust, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in United Lincolnshire Hospitals NHS Trust, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".